SV1999000149A - 1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb - Google Patents

1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb

Info

Publication number
SV1999000149A
SV1999000149A SV1999000149A SV1999000149A SV1999000149A SV 1999000149 A SV1999000149 A SV 1999000149A SV 1999000149 A SV1999000149 A SV 1999000149A SV 1999000149 A SV1999000149 A SV 1999000149A SV 1999000149 A SV1999000149 A SV 1999000149A
Authority
SV
El Salvador
Prior art keywords
aluters
inhibitors
tetrahidroquinolinas
carboxiamino
ref
Prior art date
Application number
SV1999000149A
Other languages
English (en)
Inventor
Michael Paul Deninno
Christian James Mularski
Roger Benjamin Ruggeri
Ronald Thure Wester
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV1999000149A publication Critical patent/SV1999000149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INHIBIDORES DE LA PROTEINA DE TRANSFERENCIA DEL ESTER COLESTERILICO , COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS INHIBIDORES Y EL USO DE DICHOS INHIBIDORES PARA ELEVAR CIERTOS NIVELES DE LIPIDOS EN PLASMA, INCLUYENDO LIPOPROTEINAS DE ALTA DENSIDAD DE COLESTEROL Y PARA DISMINUIR CIERTOS OTROS NIVELES DE LIPIDOS EN PLASMA, TALES COMO LDL -COLESTEROL Y TRIGLICERIDOS, Y POR CONSIGUIENTE PARA TRATAR ENFERMEDADES QUE SON EXACERBADAS POR BAJOS NIVELES DE HDL-COLESTEROL Y/O ALTOS NIVELES DE LDL COLESTEROL Y TRIGLICERIDOS, TALES COMO ATEROSCLEROSIS Y ENFERMEDADES CARDIOVASCULARES EN ALGUNOS MAMIFEROS INCLUYENDO SERES HUMANOS.
SV1999000149A 1998-09-17 1999-09-10 1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb SV1999000149A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10092998P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
SV1999000149A true SV1999000149A (es) 2000-07-06

Family

ID=22282259

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000149A SV1999000149A (es) 1998-09-17 1999-09-10 1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb

Country Status (25)

Country Link
US (2) US6147090A (es)
EP (1) EP1114033B1 (es)
JP (1) JP3655193B2 (es)
AR (1) AR021482A1 (es)
AT (1) ATE277906T1 (es)
AU (1) AU5439899A (es)
BR (1) BR9913842A (es)
CA (1) CA2344556A1 (es)
CO (1) CO5150220A1 (es)
DE (1) DE69920727T2 (es)
DK (1) DK1114033T3 (es)
DZ (1) DZ2889A1 (es)
ES (1) ES2228086T3 (es)
GT (1) GT199900149A (es)
HN (1) HN1999000155A (es)
MA (1) MA26687A1 (es)
MY (1) MY121838A (es)
PA (1) PA8481501A1 (es)
PE (1) PE20001048A1 (es)
PT (1) PT1114033E (es)
SI (1) SI1114033T1 (es)
SV (1) SV1999000149A (es)
TN (1) TNSN99172A1 (es)
TW (1) TWI232859B (es)
WO (1) WO2000017166A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
ATE524163T1 (de) 2000-04-10 2011-09-15 Teva Pharma Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
AU2002306868A1 (en) * 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
HUP0400263A2 (hu) * 2001-06-21 2005-03-29 Pfizer Products Inc. Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE60233874D1 (de) 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
BR0215240A (pt) * 2001-12-19 2004-10-26 Atherogenics Inc Derivados de calcona e seu uso no tratamento de doenças
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CA2474838C (en) * 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2003063868A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003269327A1 (en) * 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
KR100857759B1 (ko) * 2003-03-17 2008-09-09 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
MXPA05009976A (es) * 2003-03-17 2005-11-04 Japan Tobacco Inc Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7317025B2 (en) 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
CA2554982A1 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
ATE442358T1 (de) 2003-10-08 2009-09-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2005097806A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
KR20080097426A (ko) 2006-01-18 2008-11-05 쉐링 코포레이션 칸나비노이드 수용체 조절제
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
BRPI0707561A2 (pt) * 2006-02-07 2011-05-10 Hoffmann La Roche derivados de benzamida e de heteroareno
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
TW200811101A (en) * 2006-07-14 2008-03-01 Ranbaxy Lab Ltd Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
ES2533910T3 (es) 2007-04-13 2015-04-15 Kowa Company, Ltd. Compuesto novedoso de pirimidina que tiene estructura de dibencilamina y medicamento que comprende el compuesto
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CA2692268A1 (en) 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8722882B2 (en) 2008-12-23 2014-05-13 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
CA2747809A1 (en) 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010114957A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
EP2504010A4 (en) 2009-11-23 2013-04-17 Merck Sharp & Dohme Fused Bicyclic Pyrimidine Derivatives and Methods of Use Therefor
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
JP2022505264A (ja) * 2018-10-17 2022-01-14 デューク・ユニヴァーシティ 神経保護剤として使用するためのキノンレダクターゼ２阻害剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
AU5439899A (en) 2000-04-10
DZ2889A1 (fr) 2003-12-15
TNSN99172A1 (fr) 2005-11-10
AR021482A1 (es) 2002-07-24
CO5150220A1 (es) 2002-04-29
US6147090A (en) 2000-11-14
DE69920727D1 (en) 2004-11-04
BR9913842A (pt) 2001-06-12
HN1999000155A (es) 2000-01-12
DK1114033T3 (da) 2004-12-20
ES2228086T3 (es) 2005-04-01
DE69920727T2 (de) 2006-03-09
MY121838A (en) 2006-02-28
ATE277906T1 (de) 2004-10-15
EP1114033A1 (en) 2001-07-11
JP2002526477A (ja) 2002-08-20
JP3655193B2 (ja) 2005-06-02
PE20001048A1 (es) 2000-10-17
PA8481501A1 (es) 2001-12-14
TWI232859B (en) 2005-05-21
CA2344556A1 (en) 2000-03-30
US6395751B1 (en) 2002-05-28
WO2000017166A1 (en) 2000-03-30
EP1114033B1 (en) 2004-09-29
PT1114033E (pt) 2004-12-31
SI1114033T1 (en) 2005-02-28
MA26687A1 (fr) 2004-12-20
GT199900149A (es) 2001-03-03

Similar Documents

Publication Publication Date Title
SV1999000149A (es) 1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb
PA8481401A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino
PA8481201A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino
PA8537201A1 (es) Agonistas de ppar
GT200300021A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
UY28097A1 (es) Activadores de ppar
PA8539101A1 (es) Compuestos de ppar
PA8598901A1 (es) Compuesto de quinolina y quinoxalina
BRPI0410479A (pt) derivados de tetraidroisoquinolina como ativadores do ppar-(alfa)
CA2282183A1 (en) Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
BRPI0518476A2 (pt) compostos e derivados de dibenzil amina
NO993096L (no) Orale cyklosporinformuleringer
CR9012A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
ES2190082T3 (es) Concentrados estables de vitamina c.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
AR006616A1 (es) Derivados carboxilicos utiles como inhibidores de los receptores de las endotelinas y composiciones farmaceuticas que los contienen
BRPI0414671A (pt) inibidores da cetp e metabolitos dos mesmos
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
ES2163634T3 (es) Benzopiranos y composiciones farmaceuticas que les contienen.
ATE234106T1 (de) Enterales pharmazeutisches präparat
ECSP993134A (es) 1,2,3,4- tetrahidroquinolinas -2 -sustituidas 4- carboxiamino sustituidas
ECSP993135A (es) 1,2,3,4- tetrahidroquinolinas -2 -sustituidas 4- amino sustituidas
PA8589501A1 (es) Activadores de ppar
ECSP993136A (es) 4- carboxiamino- 2- metil- 1,2,3,4- tetrahidroquinolinas
DOP2003000762A (es) Activadores de ppar

Legal Events

Date Code Title Description
FD Lapse